About Castle Biosciences
Castle Biosciences is a company based in Pittsburgh (United States) founded in 2008 was acquired by Castle Biosciences in October 2021. It operates as a HealthTech. Castle Biosciences has raised $14.18 million across 10 funding rounds from investors including UPMC, Castle Biosciences and NIH. Castle Biosciences offers products and services including TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma. Castle Biosciences operates in a competitive market with competitors including PAVmed, Previse, Cyted, Lucid Diagnostics and BeamLine Diagnostics, among others.
- Headquarter Pittsburgh, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Castle Biosciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$14.18 M (USD)
in 10 rounds
-
Latest Funding Round
$2.5 M (USD), Series B
Mar 21, 2018
-
Investors
UPMC
& 7 more
-
Employee Count
Employee Count
-
Acquired by
Castle Biosciences
(Oct 22, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Castle Biosciences
Castle Biosciences offers a comprehensive portfolio of products and services, including TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Risk of progression to esophageal cancer is predicted.
Melanoma progression risk is assessed for patients.
Squamous cell carcinoma risk is evaluated accurately.
Uveal melanoma metastatic risk is determined precisely.
Melanoma diagnosis is supported through tissue analysis.
Funding Insights of Castle Biosciences
Castle Biosciences has successfully raised a total of $14.18M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $2.5 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series B — $2.5M
-
First Round
First Round
(12 Nov 2009)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2018 | Amount | Series B - Castle Biosciences | Valuation | Illumina Ventures |
|
| Aug, 2016 | Amount | Series B - Castle Biosciences | Valuation | UPMC | |
| Oct, 2015 | Amount | Grant - Castle Biosciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Castle Biosciences
Castle Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include UPMC, Castle Biosciences and NIH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health tech startups are invested in by Illumina Ventures.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investment and support are provided for Pennsylvania's tech-based companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Castle Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Castle Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Castle Biosciences Comparisons
Competitors of Castle Biosciences
Castle Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PAVmed, Previse, Cyted, Lucid Diagnostics and BeamLine Diagnostics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of medical devices and biomarkers to detect various diseases
|
|
| domain | founded_year | HQ Location |
Cancer detection and prevention solutions are developed by Previse.
|
|
| domain | founded_year | HQ Location |
Non-endoscopic diagnostics for early gastrointestinal disease detection are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic kits for esophageal cancer biomarkers are developed.
|
|
| domain | founded_year | HQ Location |
Offers bedside pre-screening technology solutions for cancer detection.
|
|
| domain | founded_year | HQ Location |
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Castle Biosciences
Frequently Asked Questions about Castle Biosciences
When was Castle Biosciences founded?
Castle Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Castle Biosciences located?
Castle Biosciences is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Is Castle Biosciences a funded company?
Castle Biosciences is a funded company, having raised a total of $14.18M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.2M, raised on Nov 12, 2009.
What does Castle Biosciences do?
Precision diagnostic and prognostic tests are developed by Castle Biosciences for various medical conditions. Focus is placed on dermatology, gastroenterology, and ophthalmology sectors. Solutions such as TissueCypher for Barretts esophagus, DecisionDx-Melanoma for cutaneous melanoma, and DecisionDx-UM for uveal melanoma are provided. Risk stratification and personalized patient management are enabled through AI-driven spatial biology and gene expression profiling technologies. Clinical decision-making is supported by offering actionable insights to healthcare providers for cancer risk assessment and treatment planning.
Who are the top competitors of Castle Biosciences?
Castle Biosciences's top competitors include Lucid Diagnostics, PAVmed and Previse.
What products or services does Castle Biosciences offer?
Castle Biosciences offers TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma.
Who are Castle Biosciences's investors?
Castle Biosciences has 8 investors. Key investors include UPMC, Castle Biosciences, NIH, Geisinger, and Ben Franklin Technology Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.